Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Insider Exodus Casts Shadow Over NuScale Power’s Nuclear Ambitions

Dieter Jaworski by Dieter Jaworski
October 13, 2025
in Analysis, Insider Trading, Renewable Energy, Trading & Momentum
0
Nuscale Power Stock
0
SHARES
15
VIEWS
Share on FacebookShare on Twitter

NuScale Power shares are navigating turbulent trading conditions characterized by extreme price swings and concerning insider liquidation patterns. Despite the company’s celebrated technological advancements, transaction data reveals a troubling disconnect between corporate achievements and executive confidence.

Significant Insider Liquidations Raise Concerns

Corporate insiders have executed substantial share disposals over the recent quarter, creating headwinds for investor sentiment. The most dramatic transaction occurred on September 19th, when a company director divested 2.37 million shares at an average price of $43.99, generating proceeds of approximately $104.37 million.

Equally noteworthy was Fluor Corporation’s complete exit from its position. On October 7th and 8th, the entity sold 909,551 shares across prices ranging from $39.42 to $43.13, realizing total proceeds of $36.87 million. This transaction eliminated Fluor’s direct holdings in the company entirely.

The cumulative picture over the past 90 days presents a stark narrative: insiders have transferred 15.05 million shares valued at $606.76 million, signaling substantial internal divestment from the nuclear technology firm.

Trading Volatility Reaches Extreme Levels

Friday’s session exemplified the stock’s turbulent nature, with shares declining 3.37% to close at $39.24. More alarming than the price drop was the trading range, which spanned 14.65% between the day’s peak and trough. As prices retreated, trading volume surged to 36 million shares—an increase of 14 million shares from previous levels—representing approximately $1.41 billion in transaction value.

Despite recent pressure, the equity shows mixed performance across different time horizons. The stock has gained 3.26% over two weeks and advanced 12.7% throughout the past three months. However, it has underperformed the broader technology sector, which returned 15.7% over the same quarterly period. The 52-week range between $11.08 and $53.50 underscores the security’s exceptional volatility.

Should investors sell immediately? Or is it worth buying Nuscale Power?

Nuclear Technology Developments Provide Counterbalance

Amid the selling pressure and price fluctuations, NuScale continues to achieve significant operational milestones:

  • Historic Power Project: The company is supporting development of up to 6 gigawatts of small modular reactor capacity across seven U.S. states, representing the largest SMR project in American history through its partnership with the Tennessee Valley Authority.

  • Regulatory Milestone: The Nuclear Regulatory Commission granted design approval for NuScale’s 77-megawatt reactor during the second quarter of 2025.

  • New Coverage Initiation: RBC Capital Markets commenced coverage with a “Sector Perform” rating and established a $35.00 price target, though classified the investment as “Speculative Risk.”

The fundamental question facing investors is whether NuScale’s technological progress can eventually translate into sustainable share price appreciation despite the overwhelming insider selling. The upcoming quarterly earnings call scheduled for October 7th may provide crucial insights. Until then, market participants must weigh promising nuclear technology developments against concerning internal transaction patterns in what remains highly volatile trading conditions.

Ad

Nuscale Power Stock: Buy or Sell?! New Nuscale Power Analysis from February 7 delivers the answer:

The latest Nuscale Power figures speak for themselves: Urgent action needed for Nuscale Power investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Nuscale Power: Buy or sell? Read more here...

Tags: Nuscale Power
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

CrossFirst Bankshares Stock
Analysis

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Myers Industries Stock
Analysis

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
Riley Exploration Permian Stock
Analysis

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

February 7, 2026
Next Post
Boeing Stock

Boeing Faces Mounting Regulatory Scrutiny Amid Safety Incidents

Qualcomm Stock

Chipmaker Qualcomm Faces Dual Threat from Trade Wars and Regulatory Scrutiny

QuantumScape Stock

Solid-State Battery Pioneer QuantumScape Forges Critical Manufacturing Partnerships

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com